SCHEMBL404165

SCHEMBL404165

CCOC(=O)c1sc(Cl)nc1-c1ncnn1C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
HSD17B10 Q99714 2/20 0.41
MAPT P10636 2/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
DHODH Q02127 4/20 0.39
CDC7 O00311 4/20 0.39
DBF4 Q9UBU7 4/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
CYP1A2 P05177 2/20 0.38
MEN1 O00255 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
FBP1 P09467 1/20 0.38
MAPK1 P28482 1/20 0.38
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL509631 0.87 ADORA2A (0.37) ALDH1A1HSD17B10MAPTHPGDSMN1; SMN2
SCHEMBL401914 0.86 ALDH1A1 (0.40) ALDH1A1HSD17B10MAPTTRPM8DHODH
SCHEMBL404561 0.85 ALDH1A1 (0.58) ALDH1A1HSD17B10MAPTDHODHCDC7
SCHEMBL404775 0.84 FBP1 (0.39) ALDH1A1HSD17B10MAPTTRPM8DHODH
SCHEMBL13330064 0.83 ALDH1A1 (0.49) ALDH1A1MAPTHPGDSMN1; SMN2KMT2A
SCHEMBL404807 0.81 LMNA (0.40) ALDH1A1HSD17B10MAPTTRPM8DHODH
SCHEMBL404166 0.80 NPC1 (0.46) ALDH1A1HSD17B10MAPTTRPM8DHODH
SCHEMBL3400633 0.77 NOTUM (0.40) ALDH1A1HSD17B10MAPTTRPM8DHODH
SCHEMBL1505433 0.76 LMNA (0.48) ALDH1A1HSD17B10MAPTTRPM8DHODH
SCHEMBL3406836 0.74 CDC7 (0.48) ALDH1A1HSD17B10MAPTTRPM8CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022107-A1 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2012-01-26 US disclosed
US-20120022107-A1 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2012-01-26 US disclosed
US-20120022107-A1 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2012-01-26 US disclosed
EP-2379545-A1 2- (PIPERIDIN-1-YL) -4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS AstraZeneca AB (SE) 2011-10-26 EP disclosed
WO-2010067125-A1 2- (PIPERIDIN-1-YL) -4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022107-A1 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS PIR, TLR5, ALPI ALDH1A1 57/4885HSD17B10 3230/4885MAPT 2750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.